Skip to main content
Top
Published in: Internal and Emergency Medicine 1/2019

01-01-2019 | IM - COMMENTARY

Silybin and metabolic disorders

Authors: Pasquale Pignatelli, Roberto Carnevale, Danilo Menichelli

Published in: Internal and Emergency Medicine | Issue 1/2019

Login to get access

Excerpt

Mediterranean diet represents a fundamental strategy in the prevention of cardiovascular and metabolic disorders as demonstrated by observational and interventional trials [1]. Among the most represented elements of the Mediterranean diet are polyphenols that display protective effects on cardiometabolic disorders by counteracting oxidative stress that represent a key point of the preventive strategy in this setting. Hence, oxidative stress seems to be involved in both cardiovascular and metabolic disorders [2]. Indeed, atherosclerotic disease is associated with increased level of oxidative stress [3] as well as metabolic disorders such as non-alcoholic fatty liver disease (NAFLD) [4] and diabetes [5] (Fig. 1).
Literature
8.
go back to reference Trouillas P, Marsal P, Svobodova A, Vostalova J, Gazak R, Hrbac J, Sedmera P, Kren V, Lazzaroni R, Duroux JL, Walterova D (2008) Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. J Phys Chem A 112(5):1054–1063. https://doi.org/10.1021/jp075814h CrossRefPubMed Trouillas P, Marsal P, Svobodova A, Vostalova J, Gazak R, Hrbac J, Sedmera P, Kren V, Lazzaroni R, Duroux JL, Walterova D (2008) Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. J Phys Chem A 112(5):1054–1063. https://​doi.​org/​10.​1021/​jp075814h CrossRefPubMed
9.
go back to reference Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G (2002) Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab 15(4):222–231PubMed Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G (2002) Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab 15(4):222–231PubMed
10.
go back to reference Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M (2006) The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 20(12):1036–1039. https://doi.org/10.1002/ptr.1988 CrossRefPubMed Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M (2006) The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 20(12):1036–1039. https://​doi.​org/​10.​1002/​ptr.​1988 CrossRefPubMed
12.
go back to reference Germano G, Sanguigni V, Pignatelli P, Caccese D, Lenti L, Ragazzo M, Lauro R, Violi F (2004) Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. J Hypertens 22(6):1151–1156CrossRefPubMed Germano G, Sanguigni V, Pignatelli P, Caccese D, Lenti L, Ragazzo M, Lauro R, Violi F (2004) Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. J Hypertens 22(6):1151–1156CrossRefPubMed
Metadata
Title
Silybin and metabolic disorders
Authors
Pasquale Pignatelli
Roberto Carnevale
Danilo Menichelli
Publication date
01-01-2019
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 1/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-018-1968-x

Other articles of this Issue 1/2019

Internal and Emergency Medicine 1/2019 Go to the issue

CE - MEDICAL ILLUSTRATION

A button battery in the nose

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine